ATS AII

Welcome to the American Thoracic Society's AII Assembly Twitter feed. Tweets by @asquental
🦋

[ATS AII @ATS_AII]

Having trouble keeping track of all of the platforms that we post content on? Follow us on linktree where we have all of our social media platforms organized in one convenient location!

https://t.co/MPw44kJOGN

[ATS AII @ATS_AII]

Save the date! Are you a basic, translational or PhD scientist wondering how to get involved in ATS? Join scientists with ATS leadership experience on Tuesday, April 6 at 2 PM ET for practical ways to start. Register now! #AII https://t.co/zEbvJwC28Y

[ATS AII @ATS_AII]

Can severe asthma change the brain? In a small ERS 2026 study, adults with severe type 2 asthma showed white matter and hippocampal differences vs mild to moderate asthma, linked to more type 2 inflammation. Check it out! #AII https://t.co/YFFdneL5fy

[ATS AII @ATS_AII]

Only two weeks left to get your abstract in! ATS 2027 abstract submission closes Wednesday, Nov 4 at 5 PM ET. Fellows, this is your nudge to talk to your mentor and submit. We would love to see a big AII showing in New Orleans! https://t.co/FJJtDZjPCa #AII

[ATS AII @ATS_AII]

Do your young asthma patients live with someone who vapes? In 48,000+ primary care visits, kids exposed to e-cigarettes at home had more flares (AAP 2026). Make sure to ask! #AII https://t.co/qfkTwVQGnF

[American Thoracic Society (ATS) @atscommunity]

If you're attending #CHEST2026, be sure to visit the ATS Booth! We're at booth #796. The Executive Committee will be visiting the booth on Monday, Oct. 19 from 10 a.m. to 4 p.m.

[ATS AII @ATS_AII]

So proud to see our own on the #CHEST2026 stage this morning! Dr. Sara Assaf and Dr. Neha Solanki joined Dr. Nicola Hanania and Dr. Diego Maselli to talk about raising the bar in asthma care, moving toward clinical remission and disease modification.

[ATS AII @ATS_AII]

By 2050, an estimated 45.7 million people in the US will have asthma. A new state-by-state GBD 2023 analysis in The Lancet Respiratory Medicine found high BMI was the leading modifiable risk factor for asthma burden. Check it out! #AII https://t.co/t0m5JiULKv

[ATS AII @ATS_AII]

Heading into winter? In a post hoc analysis of BOREAS and NOTUS presented at ERS 2026, dupilumab lowered exacerbations in every season, by 26% to 33% vs placebo, in COPD with type 2 inflammation. Check it out! #AII https://t.co/kd6kJ13Fqh

[ATS AII @ATS_AII]

Have your pregnant patients asked how to protect their baby from RSV? New CDC data in Pediatrics: maternal RSV vaccination was 82% effective and nirsevimab 77% effective against infant RSV hospitalization in 2024 to 2025. #AII https://t.co/Mjxn7Yxim0

[ATS AII @ATS_AII]

That's a wrap on our 2026 AII Abstract Scholarship Awardee Presentations! Congratulations to all of our awardees, and thank you to everyone who joined us across all three sessions. We can't wait to see what you do next! #AII

[ATS AII @ATS_AII]

It's TODAY at 10 AM ET! Join us for Part 3 of our 2026 AII Abstract Scholarship Awardee Presentations and see what our final group of awardees has been working on. Don't miss it! #AII https://t.co/apBXmJ6Rz9

[ATS AII @ATS_AII]

Is zafirlukast a reasonable alternative to montelukast, given the boxed warning? Members are weighing neuropsychiatric reporting data, liver risk, AERD and where LTRAs fit with biologics. Join the conversation on ATS Doc Matter! #AII https://t.co/2IuQepw3LL

[ATS AII @ATS_AII]

Can a routine chest CT predict pneumonitis before immunotherapy even starts? Jia Wu, PhD, and colleagues at MD Anderson built CIPHER, an AI model that outperformed clinical and radiomics approaches. Check it out! #AII https://t.co/15SXUJV6Xv

[ATS AII @ATS_AII]

More time to nominate! ATS Respiratory Health Award nominations have been extended to Monday, Oct 26. Know a colleague who deserves the Outstanding Clinician, Outstanding Educator or Trudeau Medal? Make sure to nominate them! #AII https://t.co/lgsccAMKyc

[ATS AII @ATS_AII]

It's TODAY at 11 AM ET! Join us for Part 2 of our 2026 AII Abstract Scholarship Awardee Presentations, including new work on CT high-attenuation regions and lung function response in severe asthma. Don't miss it! #AII https://t.co/9DNZEx2q7U

[ATS AII @ATS_AII]

Only two days left! Proposals for the ATS 2027 Networking Super Center Learning Studio close Wednesday, Oct 14. If you have taught a hands-on, small-group session that worked, make sure to get it in. We would love to see AII on that schedule! https://t.co/FJJtDZjPCa #AII

[ATS AII @ATS_AII]

Join us Monday, November 2 at 1:30 PM ET for Neuroimmune Interactions in the Lung with Dr. Allison Fryer of Oregon Health & Science University, this year's Solbert Permutt Trailblazer Award winner! Make sure to register. #AII https://t.co/yz82YwUITx

[ATS AII @ATS_AII]

Could an IPF drug help severe asthma? In cell, lung slice and mouse models, pirfenidone relaxed airway smooth muscle and blocked neutrophilic inflammation. Check out this Red Journal editorial on the preclinical work by Xie and colleagues! #AII https://t.co/ICAbBsnBwf

[ATS AII @ATS_AII]

Have you noticed how many of your patients support vaccines but aren't sure which ones they need? In a new @nfidvaccines survey, only 48% of US adults tried to get a flu, COVID-19, RSV, or pneumococcal vaccine last year. Make sure to ask them! #AII https://t.co/8dwNg557S3

[ATS AII @ATS_AII]

Don't miss our 2026 AII Abstract Scholarship Awardee Presentations next week! Join us Monday 10/12 at 11 AM ET for Part 2 and Thursday 10/15 at 10 AM ET for Part 3. Register for Part 2 here! #AII https://t.co/9DNZEx2q7U